Insulet (PODD) Projected to Post Earnings on Wednesday

Insulet (NASDAQ:PODD) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $768.3080 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Insulet Stock Performance

NASDAQ:PODD opened at $242.74 on Monday. The stock has a market capitalization of $17.08 billion, a P/E ratio of 70.36, a price-to-earnings-growth ratio of 1.37 and a beta of 1.41. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. Insulet has a 1 year low of $230.05 and a 1 year high of $354.88. The firm has a 50 day moving average of $277.19 and a 200-day moving average of $306.43.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PODD. UBS Group reiterated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. BTIG Research lifted their price target on Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a report on Friday, November 21st. Raymond James Financial upped their price target on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Leerink Partners raised their price objective on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Finally, Sanford C. Bernstein dropped their target price on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating for the company in a research note on Friday, January 9th. Twenty research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $374.10.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vident Advisory LLC raised its holdings in Insulet by 28.7% in the second quarter. Vident Advisory LLC now owns 1,058 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 236 shares during the period. Voleon Capital Management LP acquired a new stake in Insulet during the 2nd quarter worth $303,000. Teza Capital Management LLC bought a new position in Insulet during the second quarter worth about $223,000. Brevan Howard Capital Management LP bought a new position in Insulet during the second quarter worth about $328,000. Finally, Zions Bancorporation National Association UT grew its stake in Insulet by 107.5% in the fourth quarter. Zions Bancorporation National Association UT now owns 359 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 186 shares during the period.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.